Shared-care Guidelines
Click here for a downloadable word document of the shared care agreement forms:
DMARDs Shared Care Agreement (Version 1.1)
Generic Shared Care Agreement Form
This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.
This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.
Treatment of active rheumatoid arthritis and active psoriatic arthritis.
Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic
arthritis, severe psoriatic arthritis, mild to moderate Crohn’s disease
Unlicensed: Severe Eczema, Lichen Planus, Felty’s syndrome, severe Crohn’s disease
N.B. Not all brands/formulations are licensed for all indications – please refer to individual SPCs
Licensed: Severe active rheumatoid arthritis, including juvenile forms, Wilson's disease (hepatolenticular degeneration) in adults and children (0 to 18 years).
To extend life or the time to mechanical ventilation for adult patients with amyotrophic lateral sclerosis (ALS) 1,2, variant of Motor Neurone Disease (MND). Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other forms of MND. Riluzole should only be initiated by a neurological specialist with expertise in the management of MND (as per NICE TA 20, 2001)
It is expected that most patients will be managed by secondary care however this guideline is those patients who need to be managed in community
Licensed: Rheumatoid arthritis; ulcerative colitis, Crohn’s disease in adults and children
Unlicensed: Sero-negative spondyloarthropathy including psoriatic arthritis and psoriasis.